And on to the latest on Samsung BioLogics and the accounting fraud scandal swirling around the firm.
The Financial Supervisory Service says. a 2015 accounting breach by the Samsung affiliate was *intentional and the biopharmaceutical firm clearly violated accounting rules.
The financial regulator adds it will refer the case to the prosecution.
The decision comes after a months-long review of the company's book-keeping when it switched in 2015 to valuing its stakes in drugmaker Samsung Bioepis. at fair market value instead of at book-value.
Following the announcement,. Samsung BioLogics expressed regret, adding that it had no "motive" to intentionally violate accounting rules and that it will consider taking legal action against the ruling.